Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5.
France NP, Rubino C, Safir MC, Maurer M, Duong T, Singamsetty D, Abd-Elaziz K, Chou T, Sankaranarayanan S, Ettema M, Cosford R, Dogterom P, Liu E, Barlow C. France NP, et al. Among authors: abd elaziz k. Clin Pharmacol Drug Dev. 2023 Jun;12(6):625-638. doi: 10.1002/cpdd.1256. Epub 2023 May 16. Clin Pharmacol Drug Dev. 2023. PMID: 37191222 Clinical Trial.
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).
Aslanis V, Abd-Elaziz K, Slack RJ, Brinch A, Gravelle L, Morley W, Phung D, Herman K, Holyer I, Poulsen KK, Dogterom P, Tantawi S, Zetterberg FR, Jacoby B, Schambye H, Lindmark B. Aslanis V, et al. Among authors: abd elaziz k. Cancer Chemother Pharmacol. 2024 Nov;94(5):707-720. doi: 10.1007/s00280-024-04710-3. Epub 2024 Aug 21. Cancer Chemother Pharmacol. 2024. PMID: 39167148 Clinical Trial.
First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.
Abd-Elaziz K, Voors-Pette C, Wang KL, Pan S, Lee Y, Mao J, Li Y, Chien B, Lau D, Diamant Z. Abd-Elaziz K, et al. Clin Drug Investig. 2021 Jan;41(1):65-76. doi: 10.1007/s40261-020-00981-9. Epub 2020 Dec 17. Clin Drug Investig. 2021. PMID: 33331980 Clinical Trial.
Safety, Tolerability, Pharmacokinetics and Initial Pharmacodynamics of a Subcommissural Organ-Spondin-Derived Peptide: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose First-in-Human Study.
Bourdès V, Dogterom P, Aleman A, Parmantier P, Colas D, Lemarchant S, Marie S, Chou T, Abd-Elaziz K, Godfrin Y. Bourdès V, et al. Among authors: abd elaziz k. Neurol Ther. 2022 Sep;11(3):1353-1374. doi: 10.1007/s40120-022-00380-6. Epub 2022 Jul 2. Neurol Ther. 2022. PMID: 35779189 Free PMC article.
Oral follicle-stimulating hormone agonist tested in healthy young women of reproductive age failed to demonstrate effect on follicular development but affected thyroid function.
Gerrits MG, Kramer H, el Galta R, van Beerendonk G, Hanssen R, Abd-Elaziz K, Klipping C, Duijkers I, Stoch SA. Gerrits MG, et al. Fertil Steril. 2016 Apr;105(4):1056-1062.e4. doi: 10.1016/j.fertnstert.2015.12.017. Epub 2016 Jan 6. Fertil Steril. 2016. PMID: 26769303 Free article. Clinical Trial.
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.
Ferguson M, Schwarz TF, Núñez SA, Rodríguez-García J, Mital M, Zala C, Schmitt B, Toursarkissian N, Mazarro DO, Großkopf J, Voors-Pette C, Mehta H, Hailemariam HA, de Heusch M, Salaun B, Damaso S, David MP, Descamps D, Hill J, Vandermeulen C, Hulstrøm V; RSV OA=ADJ-018 Study Group. Ferguson M, et al. Clin Infect Dis. 2024 Oct 15;79(4):1074-1084. doi: 10.1093/cid/ciae364. Clin Infect Dis. 2024. PMID: 39099093 Free PMC article. Clinical Trial.
51 results